AiViva BioPharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, AiViva BioPharma sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
AiViva BioPharma: 5 sponsored US clinical trials, none currently recruiting.
AiViva BioPharma sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Macular Edema, with 1 trials.
Upper-quartile sponsor footprint
AiViva BioPharma sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
NCT05698329
Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy
NCT04827875
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration
NCT04422899
Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype
NCT04470726
A Safety and Efficacy Study to Evaluate AIV001 in Wound Healing Following Surgical Incision
NCT03639883
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Therapeutic Areas
How the AiViva BioPharma early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 4 completed (80%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Macular Edema (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
AiViva BioPharma: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
AiViva BioPharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this AiViva BioPharma page
5 registered trials is a research-attention snapshot, not an endorsement of AiViva BioPharma or any single study.
- None of AiViva BioPharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Macular Edema is the condition AiViva BioPharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Macular Edema trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AiViva BioPharma pipeline card: 5 registered trials from official public datasets.Report a data error.